You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

Citation Tools

Article menu

Download PDFPDF

Spondyloarthritis
Original research
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Denis A, Sztejkowski C, Arnaud L, et al
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
RMD Open 2023;9:e003279. doi: 10.1136/rmdopen-2023-003279